Zurich Cantonal Bank
BIS icon

Zurich Cantonal Bank’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Zurich Cantonal Bank’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,000
Closed -$1.14M – 967
2014
Q2 		$1.14M Buy
+2,000
New +$1.38M 0.03% 527

Other funds holding BIS

HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BMO
Beck Mack & Oliver New York $4.85B AUM 9.66% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Zurich Cantonal Bank's BIS Position: Q3 2014 in Review

Zurich Cantonal Bank sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2014, closing a stake of 2,000 shares — an estimated $1.14M sold.

Zurich Cantonal Bank first reported a position in BIS in Q2 2014 and held it in 1 quarter. The position peaked at $1.14M in Q2 2014. 16 funds tracked by Wall St. Rank hold BIS as of Q3 2014.

  • Zurich Cantonal Bank reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2014 after selling out during the quarter.
  • Zurich Cantonal Bank sold 2,000 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2014, an estimated $1.14M.
  • Zurich Cantonal Bank first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2014 and held it in 1 quarter.
  • Zurich Cantonal Bank's ProShares UltraShort NASDAQ Biotechnology position peaked at $1.14M in Q2 2014.
  • 16 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2014.

Based on Zurich Cantonal Bank's 13F filing for Q3 2014, filed 28 Oct 2014.